Abstract
Sacubitril/valsartan (SAC/VAL) and angiotensin receptor blockers (ARB) are recommended therapy for heart failure with preserved ejection fraction (HFpEF), but little is known about their real-world comparative effectiveness and costs. We aimed to assess comparative effectiveness of SAC/VAL vs. ARB for preventing HF-related and all-cause hospitalizations in patients with HFpEF and their related medical costs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
